Radiation, Chemotherapy, and Immunotherapy for Rectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Rectal cancer confirmed by biopsy, located within 10 cm of the anal opening
- Cancer has not spread to distant organs
- No prior cancer treatment (radiation, chemotherapy, immunotherapy, or targeted therapy)
- Good overall health and ability to tolerate treatment (ECOG performance status 0–1)
- Blood counts and liver/kidney function within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests a new combination of standard chemotherapy, immunotherapy (a drug that helps your immune system fight cancer), and a special diet and/or high-dose vitamin C before surgery for rectal cancer. It aims to shrink the tumor and improve surgery outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests giving radiation, chemotherapy, and immunotherapy before surgery for rectal cancer that has not spread far. The goal is to see if this combination shrinks the tumor more and improves outcomes before surgery.
This trial tests a combination of short-course radiation, internal radiation (brachytherapy), and several drugs to shrink rectal cancer before surgery. The goal is to improve outcomes and potentially avoid more extensive surgery.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.